Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios.

ABSTRACT:

Introduction

Optimal sequencing of therapies is an important unresolved issue in metastatic neuroendocrine neoplasms (NEN). Progression-free survival (PFS) ratios constitute a potential method for intra-patient treatment comparisons and were used in this analysis to assess the relative treatment benefit of established therapies.

Methods

This retrospective study included NEN patients of the Medical University of Vienna (treated in 2010-2024) who had metastatic disease and had received ≥ 2 palliative systemic therapies. The primary objective was the calculation of PFS ratios for therapy sequences, with the PFS ratio defined as the proportion of PFS2 (subsequent treatment) and PFS1 (prior treatment).

Results

Of the 177 patients included, 104 had neuroendocrine tumors (NE

SUBMITTER: Melhorn P 

PROVIDER: S-EPMC12660416 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature